BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. My time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to complete my PhD in molecular and cellular biology at the Rowett Research Institute. I joined the University of Aberdeen in 1996 as a post-doctoral scientist studying tumour biology and mechanisms of chemoresistance under Dr Howard Macleod and Professor Jim Cassidy. In 2014, I was appointed to establish and lead development of the Centre for Genome Enabled Biology and Medicine (CGEBM), a centre for genomics and bioinformatics at the University of Aberdeen. I continue to lead CGEBM and in 2024 I was appointed as Strategic lead for the Institute of Medical Sciences Facilities Centre at the University of Aberdeen to head the strategic direction, innovation and operational evolution of cytometry, genomics, histology, microscopy and proteomics. I have a research focus in tumour biology with a particular interest in breast cancer.
The technology hubs within the Institute of Medical Sciences Facilities Centre provide specialist expertise, infrastructure, training and a hub for methodological innovation, collaborative and interdisciplinary research design and information exchange, and bespoke research goal-oriented support in bioinformatics, cytometry, genomics, histology, microscopy and proteomics. This incorporates integrated application across technological fields in an era of multi-omics and sophisticated cellular and molecular resolution to drive understanding across diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen and beyond and addressing global challenges in human health and disease, agriculture and the environment.
Memberships and Affiliations
- Internal Memberships
-
University of Aberdeen
Aberdeen Grants Academy: Institutional Capital Equipment panel member
Research Facilities Working Group member
Research and Innovation Committee member, Institute of Medical Sciences
- External Memberships
-
2024 - Breast Cancer Now Prevention and Cure Grants Committee member.
2009 - 2014 Scientific Member, Experimental and Translational Medicine Research Committee, Chief Scientist Office.
2005 - 2009 Scientific Member, Biomedical and Therapeutics Research Committee, Chief Scientist Office.
Professional memberships
Genetics Society
British Association of Cancer Research
European Association of Cancer Research
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
I am course co-ordinator and teach MB5522 Advanced Bioinformatics and Genome Sequencing. I teach level 5 MB5021 Bioinformatics, MB5029 Toxicology and MT5515 Basic Research Methods; level 4 PA4303 Current Topics in Pharmacological research; level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and provide research project supervision to level 5 MSc students and BSc Honours students in the fields of cancer biology and genomics.
- Publications
-
Page 2 of 7 Results 11 to 20 of 66
Vgll3 interacts with Yap/Taz-Tead1-4-dependent gene expression in skeletal muscle
2019 Spring Padua Muscle Days, pp. 53-53Contributions to Journals: AbstractsFormate cross-feeding and cooperative metabolic interactions revealed by transcriptomics in co-cultures of acetogenic and amylolytic human colonic bacteria
Environmental Microbiology, vol. 21, no. 1, pp. 259-271Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1111/1462-2920.14454
- [OPEN ACCESS] https://aura.abdn.ac.uk/bitstreams/9be83065-a6da-49d0-9745-3e1b55f99183/download
- [ONLINE] View publication in Mendeley
Jaundice in newborns could be an evolutionary safeguard against death from sepsis
The ConversationContributions to Specialist Publications: ArticlesAdaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin
Scientific Reports, vol. 8, pp. 1-10Contributions to Journals: ArticlesCommon and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function
Stem Cells, vol. 35, no. 8, pp. 1958-1972Contributions to Journals: ArticlesFine mapping of genes determining extrafusal fiber properties in murine soleus muscle
Physiological Genomics, vol. 49, no. 3, pp. 141-150Contributions to Journals: ArticlesRegulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer
BMC Cancer, vol. 15, 762Contributions to Journals: ArticlesTumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
British Journal of Cancer, vol. 110, no. 6, pp. 1525-1534Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/bjc.2014.45
Influence of resistance to 5-fluorouracil and tomudex on [18F]-FDG incorporation, glucose transport and hexokinase activity
International Journal of Oncology, vol. 41, no. 1, pp. 378-382Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3892/ijo.2012.1439
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy
Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 807-818Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10549-011-1625-9